Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Apr 17, 2026·v1

Acute Myocardial Infarction

Acute Myocardial Infarction is a critical emergency requiring a coordinated "systems of care" approach. Diagnosis relies on the Universal Definition (troponin elevation + ischemia). STEMI mandates immediate reperfusion (PCI < 90 min), while NSTEMI is risk-stratified. Long-term survival depends on the prevention of adverse remodeling through DAPT, statins, ACE inhibitors, and beta-blockers.

High Evidence171 references·655 words·3 min read·v1
CardiologyEmergency MedicineIschemic Heart DiseaseSTEMINSTEMI

Quick Reference

RxDrug of choiceAspirin (324 mg load) + Ticagrelor (180 mg load) or Prasugrel (60 mg load)
AltAlternativesClopidogrel (600 mg load) if high bleeding risk or if fibrinolysis is used
⊘AvoidNSAIDs (except Aspirin), Nitrates in RV infarction, Fibrinolytics in NSTEMI
DxTest of choiceCoronary Angiography (Definitive); High-sensitivity Troponin (Biomarker)
ScKey scoreGRACE Score (Mortality), Killip Class (Heart Failure), SCAI Stage (Shock)
→When to referImmediate referral to Cardiology/Interventional Cardiology for all suspected AMI
AMI requires rapid diagnosis via ECG and troponin, followed by immediate revascularization (PCI) and dual antiplatelet therapy to minimize myocardial necrosis.
Acute myocardial infarction (AMI) is the clinical manifestation of myocardial cell death resulting from prolonged ischemia. It is defined by a rise and/or fall of cardiac troponin (cTn) with at least one value above the 99th percentile upper reference limit, accompanied by clinical evidence of ischemia such as symptoms, new ECG changes, or imaging evidence of wall motion abnormalities. AMI is broadly categorized into ST-elevation myocardial infarction (STEMI), typically indicating complete coronary occlusion, and non-ST-elevation myocardial infarction (NSTEMI).

Overview and Recommendations

Background

  • •Understand the Fourth Universal Definition of Myocardial Infarction, which classifies AMI into five types based on pathophysiology. Type 1 is spontaneous MI due to plaque rupture or erosion; Type 2 results from supply-demand imbalance (e.g., anemia, tachycardia); Type 3 is sudden cardiac death; Type 4 is related to (PCI); and Type 5 is related to coronary artery bypass grafting (CABG).
  • •Distinguish between and based on the initial electrocardiogram (ECG). STEMI requires immediate reperfusion due to transmural ischemia, while NSTEMI involves subendocardial ischemia and is managed with urgent or early invasive strategies depending on risk stratification.
  • •Recognize the significance of (CS), the most lethal complication of AMI. It is characterized by systemic hypoperfusion due to cardiac pump failure and is staged from A (at risk) to E (extremis) using the SCAI classification system.
  • •Identify non-atherosclerotic causes of MI, particularly in younger patients and women. (SCAD) is the leading cause of pregnancy-associated MI, while (Myocardial Infarction with Non-Obstructed Coronary Arteries) occurs in 5-10% of cases and requires specialized imaging like Cardiac MRI for diagnosis.
  • •Appreciate the time-dependent nature of myocardial necrosis. The "progressive phase" of active necrosis begins at symptom onset, making the "door-to-balloon" time (target < 90 minutes) the most critical metric for improving survival in obstructive cases.

Evaluation

  • •Suspect AMI in any patient presenting with acute chest pain, pressure, or discomfort, particularly if it radiates to the left arm, neck, or jaw. Be vigilant for atypical presentations in women, the elderly, and patients with diabetes, who may present with isolated dyspnea, nausea, or epigastric pain.
  • •Obtain a 12-lead ECG within 10 minutes of first medical contact. Look for persistent ST-segment elevation in two contiguous leads (≥1 mm in most leads, or age/sex-specific thresholds in V2-V3) to diagnose STEMI.
  • •Identify "Occlusion Myocardial Infarction" (OMI) patterns that may not meet formal STEMI criteria but indicate acute occlusion. These include de Winter T-waves (upsloping ST-depression with tall, symmetric T-waves), hyperacute T-waves, and Wellens' syndrome (biphasic or deeply inverted T-waves in V2-V3).
  • •Order high-sensitivity cardiac troponin (hs-cTn) immediately at presentation (H0). Utilize the H0/H1 or H0/H2 rapid rule-out/rule-in algorithms; a very low H0 value in a patient symptomatic for >3 hours can often rule out AMI, while a significant absolute delta (change) at 1 or 2 hours suggests acute injury.
  • •Perform a targeted physical examination to assess for hemodynamic stability and complications. Use the Killip classification: Class I (no heart failure), Class II (rales, S3 gallop), Class III (pulmonary edema), and Class IV ( with hypotension and hypoperfusion).
  • •Rule out life-threatening mimics using the "Triple Rule Out" approach if the diagnosis is ambiguous. Consider (tearing pain, BP discrepancy), (pleuritic pain, tachycardia), and tension pneumothorax.
  • •Calculate the GRACE or TIMI risk score to guide the urgency of intervention in NSTEMI. High-risk features (GRACE >140, dynamic ST changes) warrant an early invasive strategy within 24 hours.
  • •Utilize point-of-care to identify regional wall motion abnormalities, which support the diagnosis of AMI and help exclude mechanical complications like papillary muscle rupture or ventricular septal defects.
  • •Screen for metabolic mimics such as severe , which can produce "pseudo-infarction" ST-elevation patterns on ECG, especially in patients with known renal failure.
  • •Consider Cardiac Magnetic Resonance (CMR) imaging within 7-14 days for patients with suspected . CMR is the gold standard for differentiating MI from or by identifying specific patterns of late gadolinium enhancement (LGE).

Management

  • •Administer Aspirin 324 mg (chewed) immediately to all patients with suspected ACS unless a true allergy exists. This provides rapid platelet inhibition and is a cornerstone of early therapy.
  • •Initiate a second antiplatelet agent (P2Y12 inhibitor) as soon as possible. For STEMI or high-risk NSTEMI, preferred agents include Ticagrelor 180 mg loading dose followed by 90 mg BID, or Prasugrel 60 mg loading dose (only if coronary anatomy is known and no history of stroke/TIA).
  • •Provide anticoagulation with Unfractionated Heparin (UFH) 60 U/kg bolus (max 4000 U) followed by 12 U/kg/hr infusion, or Enoxaparin 1 mg/kg SC BID. UFH is preferred if the patient is proceeding immediately to the cath lab.
  • •Activate the cardiac catheterization laboratory immediately for any patient with STEMI. The goal is primary PCI with a door-to-balloon time of < 90 minutes at PCI-capable centers or < 120 minutes if transfer is required.
  • •Administer Fibrinolytic therapy (e.g., Tenecteplase weight-based bolus) only if primary PCI cannot be performed within 120 minutes of diagnosis and there are no contraindications (e.g., recent intracranial hemorrhage, active bleeding).
  • •Restrict supplemental oxygen to patients with SaO2 < 90% or PaO2 < 60 mmHg. Routine oxygen in normoxic patients may cause coronary vasoconstriction and increase infarct size.
  • •Manage ischemic pain with Sublingual Nitroglycerin 0.4 mg every 5 minutes (up to 3 doses). Avoid nitrates in patients with right ventricular infarction (leads V3R/V4R elevation) or recent phosphodiesterase inhibitor use (e.g., sildenafil).
  • •Stabilize by maintaining a Mean Arterial Pressure (MAP) ≥ 65 mmHg. Use Norepinephrine 0.05–1.0 µg/kg/min as the first-line vasopressor; add Dobutamine 2.5–20 µg/kg/min if hypoperfusion persists despite adequate MAP.
  • •Consider early mechanical circulatory support (MCS) with a microaxial flow pump (e.g., Impella) in patients with refractory cardiogenic shock (SCAI Stage D/E) to provide left ventricular unloading.
  • •Initiate high-intensity (e.g., Atorvastatin 80 mg daily) as soon as possible, regardless of baseline LDL levels, for their pleiotropic plaque-stabilizing effects.
  • •Start an ACE inhibitor (e.g., Lisinopril 5 mg daily) within 24 hours in patients with LVEF < 40%, hypertension, or diabetes, provided they are hemodynamically stable without hypotension.
  • •Administer oral Beta-blockers (e.g., Metoprolol succinate 25-50 mg daily) within the first 24 hours only in stable patients. Avoid in those with signs of heart failure, low output states, or risk of cardiogenic shock.
  • •Prescribe Mineralocorticoid Receptor Antagonists (MRA) like Eplerenone 25 mg daily for patients already on ACEi and Beta-blockers who have an LVEF ≤ 40% and either symptomatic heart failure or diabetes.
  • •Refer all AMI survivors to a formal cardiac rehabilitation program. Participation significantly reduces all-cause mortality and improves functional capacity post-discharge.
  • •Discharge criteria include hemodynamic stability for 24-48 hours, successful revascularization, absence of high-grade arrhythmias, and a clear plan for dual antiplatelet therapy (DAPT) adherence, typically for 12 months.

Board Review — High Yield

  • •Type 2 MI — Myocardial injury due to supply-demand mismatch (e.g., sepsis, anemia) rather than primary plaque rupture.
  • •Killip Class IV — Represents cardiogenic shock; the highest mortality risk category in AMI.
  • •de Winter T-waves — Upsloping ST-depression with tall, peaked T-waves in precordial leads; signifies acute LAD occlusion.
  • •SCAD — Spontaneous Coronary Artery Dissection; the most common cause of MI in pregnant and postpartum women.
  • •S1Q3T3 — Classic but non-specific ECG finding for pulmonary embolism, a major differential for AMI.
  • •H0/H1 Protocol — Use of high-sensitivity troponin at 0 and 1 hour to rapidly rule out (low delta) or rule in (high delta) AMI.
  • •Right Ventricular Infarct — Suspect with inferior MI + ST-elevation in V4R; treat with fluids, avoid nitrates/diuretics.
  • •Dressler Syndrome — Post-MI pericarditis occurring weeks later; autoimmune-mediated, treated with NSAIDs/Colchicine.

Deep Dive — Evidence Details

References

  1. [1]

    Di Fusco SA, Matteucci A, Alonzo A et al.. “Beta-Blocker Therapy After Myocardial Infarction: A Systematic Review and Meta-Analysis of Contemporary Randomized Controlled Trials.” International journal of molecular sciences (2026). PMID: 41828582 ↗

    L1aSR_MA_RCTCited in: Definition, Synonyms, and Classification
  2. [2]

    Yang Y, Liao M, Liu X et al.. “Prognostic Impact of Renin-Angiotensin System Inhibitors in Revascularized Patients with Acute Myocardial Infarction and Preserved or Mildly Reduced Ejection Fraction: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 41976977 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  3. [3]

    Smidtslund P, Harjutsalo V, Thorn V et al.. “Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study.” The lancet. Diabetes & endocrinology (2026). PMID: 41871591 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations
  4. [4]

    Kryeziu B, Poniku A, Henein MY et al.. “Epidemiological 11-Year Dynamics Study of Acute Myocardial Infarction: A Cohort Study in a Country with a Transitional Healthcare System.” Global heart (2026). PMID: 41766718 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification
  5. [5]

    Lu G, Wang X, Wang X et al.. “Case Report: Rapid progression of inflammation-driven coronary artery lesions in a normolipidemic patient with ANCA-associated vasculitis complicated by Stanford type A aortic dissection.” Frontiers in immunology (2026). PMID: 41909680 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  6. [6]

    Khalaf Y, Atta S, Helal A et al.. “Survival Beyond the Odds: Twelve-Week Follow-Up After Conservative Management of Post-Infarction Ventricular Free Wall Rupture.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41772389 ↗

    L4CASE_REPORTCited in: Definition, Synonyms, and Classification
  7. [7]

    Vural A, Dolanbay T, Cumaoglu MO et al.. “Metabolic risk factors associated with premature myocardial infarction in adults ≤ 35 years: a case-control study.” BMC cardiovascular disorders (2026). PMID: 41776422 ↗

    L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification
  8. [8]

    Madandar E, Zarinfar Y, Namazi MH et al.. “Associations of Endothelial-Related lncRNAs with Early-Onset STEMI: A Case-Control Study.” Journal of cardiovascular translational research (2026). PMID: 41758284 ↗

    L3bCASE_CONTROLCited in: Definition, Synonyms, and Classification
  9. [9]

    Chen S, Wang R, Ma J et al.. “Impact of a Prehospital Chest Pain Alert App-Mediated Prehospital-in-Hospital Coordination Model on Treatment Delays and Clinical Outcomes in Patients With ST-Elevation Myocardial Infarction: Protocol for a 4-Year Retrospective Real-World Cohort Study.” JMIR research protocols (2026). PMID: 41973638 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations
  10. [10]

    Zhang Y, Wang S, Fang Z et al.. “Predictive Performance of Serum Monomeric C-Reactive Protein for Major Adverse Cardiovascular Events in Patients With Acute ST-Segment Elevation Myocardial Infarction at One-Year Post-Discharge: A Retrospective Cohort Study.” British journal of hospital medicine (London, England : 2005) (2026). PMID: 41914002 ↗

    L2bCOHORTCited in: Definition, Synonyms, and Classification, Special Populations
  11. [11]

    Zhao J, Hong H, Fanaroff A et al.. “Advancing In-Hospital Mortality Prediction for Acute Myocardial Infarction: an analysis from the American Heart Association Get-With-the-Guidelines Coronary Artery Disease Registry.” American heart journal (2026). PMID: 41990900 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  12. [12]

    Ughetto A, Schrage B, Fürholz M et al.. “Beyond the STEMI Paradigm: Expanding the Scope of microAxial Flow Pump in Cardiogenic Shock.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2026). PMID: 41966345 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  13. [13]

    Speckauskiene V, Meilutyte-Lukauskiene D, Cerapaite-Trusinskiene R et al.. “Prognostic utility of Killip classification in acute myocardial infarction: a retrospective cohort analysis in contemporary clinical practice.” European heart journal open (2026). PMID: 41958748 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  14. [14]

    Aleksova A, Janjusevic M, Marketou M et al.. “Charting individualized pathways: IGF-1 and vitamin D in guiding personalized medicine for residual risk after AMI.” Progress in cardiovascular diseases (2026). PMID: 41956273 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  15. [15]

    Graves JM, Waken RJ, Wang F et al.. “Acute Myocardial Infarction in Medicare Beneficiaries During and After the COVID-19 Pandemic.” JAMA network open (2026). PMID: 41920542 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations
  16. [16]

    Kim CH, Joh HS, Kim HK et al.. “Comparison of Clinical Outcomes Between Incomplete and Complete Revascularization in NSTEMI Patients With Multivessel Disease.” JACC. Asia (2026). PMID: 41920117 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  17. [17]

    Laffan J, Gao H, Street A et al.. “Outcomes according to timely or delayed primary percutaneous coronary intervention or fibrinolysis in a national registry of patients with ST-segment elevation myocardial infarction.” Open heart (2026). PMID: 41916670 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes, Special Populations
  18. [18]

    Lugo-Gavidia LM, Saucedo JF, Arias-Mendoza A et al.. “Implementing the GWTG-CAD Program in Mexico: Feasibility, Challenges and Lessons Learned for Acute and Secondary Prevention and Management.” Journal of the American Heart Association (2026). PMID: 41914361 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations
  19. [19]

    Zhao Y, Chen XY, Zhu GJ et al.. “Incremental prognostic value of left atrial strain for heart failure-related events following ST-Segment elevation myocardial infarction.” European journal of radiology (2026). PMID: 41894993 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  20. [20]

    Pozzessere P, Di Lauro M, Incantalupo F et al.. “Evaluating the Efficacy of CPS, HEART and TIMI Score in Emergency Department Patients with Non-Traumatic Chest Pain: A Pilot Study.” Medical sciences (Basel, Switzerland) (2026). PMID: 41892866 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Special Populations
  21. [21]

    Beske RP, Klein A, Jensen LO et al.. “Early clinical recovery in STEMI cardiogenic shock: insights from the DanGer shock trial.” European heart journal. Acute cardiovascular care (2026). PMID: 41873805 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  22. [22]

    Palmisano T, Bilchick K, Guarraia D. “Hemoglobin A1c is more predictive of type 1 myocardial infarction than low-density lipoprotein or body mass index.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41864779 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  23. [23]

    Sharkey SW, Herman R, Witt DR et al.. “Performance of Artificial Intelligence-Powered ECG Analysis in Suspected ST-Segment Elevation Myocardial Infarction.” JACC. Advances (2026). PMID: 41863986 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  24. [24]

    Bilato C, Girardi G, Zuin M et al.. “Temporal trend in epidemiology and performance indicators of acute myocardial infarction: A 25 years population-based study.” International journal of cardiology (2026). PMID: 41861850 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  25. [25]

    Mavridis A, Viktorisson A, Leósdóttir M et al.. “Medication adherence after myocardial infarction: Predictors, mortality and cardiovascular outcomes.” Atherosclerosis (2026). PMID: 41856699 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes
  26. [26]

    Hu D, Wu D, Huang T et al.. “Monocyte-to-lymphocyte ratio as a predictor of left ventricular aneurysm in acute STEMI patients.” Frontiers in endocrinology (2025). PMID: 41847671 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  27. [27]

    Ahmadi-Beni M, Mokhtarian K, Mobini GR et al.. “Fasciola hepatica-Derived Proteins Shield the Heart From Type 2 Myocardial Infarction in Rats by Modulating Oxidative Stress and Inflammatory Imbalance: Insights Relevant to the Hygiene Hypothesis.” Oxidative medicine and cellular longevity (2026). PMID: 41823333 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  28. [28]

    Möser C, Prystupa K, Schön M et al.. “Cohort profile: The DIabetes and ST-segment Elevation Myocardial Infarction (DISTEMI) Study.” Cardiovascular diabetology (2026). PMID: 41821026 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification
  29. [29]

    Kuku KO, Lenselink C, Venema CS et al.. “Impact of Coronary Artery Disease Extent on GRACE Risk Score Prognostic Performance After ST-Segment-Elevation Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41804884 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes
  30. [30]

    Zhang YK, Shao X, Hu ST et al.. “Development and Validation of a Prognostic Model for One-year Mortality in Older Adults with Acute Myocardial Infarction Incorporating Activities of Daily Living Impairment.” Clinical interventions in aging (2026). PMID: 41799377 ↗

    L5OTHERCited in: Definition, Synonyms, and Classification, Prognosis and Long-term Outcomes
  31. [31]

    Morosato M, Gaspardone C, Romagnolo D et al.. “Left Main Spontaneous Coronary Artery Dissection: Clinical Features, Management, and Outcomes.” JACC. Cardiovascular interventions (2025). PMID: 40208153 ↗

    L2aSR_OBSCited in: Etiology and Triggering Factors
  32. [32]

    O'Donoghue ML, Morrow DA, Vavere AL et al.. “Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial.” Nature medicine (2025). PMID: 40999229 ↗

    L1bRCTCited in: Etiology and Triggering Factors
  33. [33]

    Gebert ZM, Kwiecinski J, Weir-McCall JR et al.. “Impact of diabetes mellitus on coronary artery plaque characteristics and outcomes in the SCOT-HEART trial.” Journal of cardiovascular computed tomography (2025). PMID: 39788814 ↗

    L1bRCTCited in: Etiology and Triggering Factors
  34. [34]

    Kolossváry M, Lin A, Kwiecinski J et al.. “Coronary Plaque Radiomic Phenotypes Predict Fatal or Nonfatal Myocardial Infarction: Analysis of the SCOT-HEART Trial.” JACC. Cardiovascular imaging (2025). PMID: 39480364 ↗

    L1bRCTCited in: Etiology and Triggering Factors
  35. [35]

    Nurmohamed NS, Min JK, Anthopolos R et al.. “Atherosclerosis quantification and cardiovascular risk: the ISCHEMIA trial.” European heart journal (2024). PMID: 39101625 ↗

    L1bRCTCited in: Etiology and Triggering Factors
  36. [36]

    Rexhaj E, Bär S, Soria R et al.. “Effects of alirocumab on endothelial function and coronary atherosclerosis in myocardial infarction: A PACMAN-AMI randomized clinical trial substudy.” Atherosclerosis (2024). PMID: 38513436 ↗

    L1bRCTCited in: Etiology and Triggering Factors
  37. [37]

    Hong XL, Loh YH, Li DB et al.. “Intracoronary administration of tenecteplase to prevent PCI-related myocardial infarction in patients with echo-attenuated coronary plaques: study protocol for a multicenter, prospective, randomized controlled trial.” Trials (2024). PMID: 39587685 ↗

    L2bTRIAL_NONRANDOMCited in: Etiology and Triggering Factors
  38. [38]

    Zhao J, Chen Z, Yang J et al.. “Effect of KLF15-Mediated Circadian Rhythm on Myocardial Infarction: A Narrative Review.” International journal of molecular sciences (2025). PMID: 40429972 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  39. [39]

    Chaturvedi A, Gadela NV, Kalra K et al.. “Non-atherosclerotic coronary causes of myocardial infarction in women.” Progress in cardiovascular diseases (2025). PMID: 39880182 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  40. [40]

    Chapman AR, Taggart C, Boeddinghaus J et al.. “Type 2 myocardial infarction: challenges in diagnosis and treatment.” European heart journal (2025). PMID: 39658094 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  41. [41]

    Juhasz V, Charlier FT, Zhao TX et al.. “Targeting the adaptive immune continuum in atherosclerosis and post-MI injury.” Atherosclerosis (2024). PMID: 39546915 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  42. [42]

    Młynarska E, Czarnik W, Fularski P et al.. “From Atherosclerotic Plaque to Myocardial Infarction-The Leading Cause of Coronary Artery Occlusion.” International journal of molecular sciences (2024). PMID: 39000400 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  43. [43]

    Katz AE, Gupte T, Ganesh SK. “From Atherosclerosis to Spontaneous Coronary Artery Dissection: Defining a Clinical and Genetic Risk Spectrum for Myocardial Infarction.” Current atherosclerosis reports (2024). PMID: 38761354 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  44. [44]

    Schelemei P, Wagner E, Picard FSR et al.. “Macrophage mediators and mechanisms in cardiovascular disease.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38275140 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  45. [45]

    Wang W, Huang B. “Recurrent Chest Pain Due to Spontaneous Coronary Artery Dissection Diagnosed by Optical Coherence Tomography.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41077821 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors
  46. [46]

    Mori T, Aoyama H, Tanaka A et al.. “Detailed Visualization of the Dissected False Lumen Using Intravascular Ultrasound, Optical Coherence Tomography, and Angioscopy in a Young Man With Acute Myocardial Infarction Caused by Spontaneous Coronary Artery Dissection.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 40437848 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors
  47. [47]

    Mumma BE, Kim JM, Rogers JH. “Chest Pain in the Setting of Acute Stress: A Tale of Two Women.” Clinical therapeutics (2024). PMID: 39578136 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors, Differential Diagnosis
  48. [48]

    Littmann L. “An unusual cause of giant T waves.” The American journal of emergency medicine (2024). PMID: 38839488 ↗

    L4CASE_REPORTCited in: Etiology and Triggering Factors
  49. [49]

    Cojocaru PA, Țieranu ML, Piorescu MTL et al.. “Myocardical Infarction in Young Adults: Revisiting Risk Factors and Atherothrombotic Pathways.” Medicina (Kaunas, Lithuania) (2025). PMID: 41011006 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  50. [50]

    Imbesi A, Greco A, Capodanno D. “Anti-inflammatory strategies for patients with atherosclerotic coronary disease.” Expert review of cardiovascular therapy (2025). PMID: 40968010 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  51. [51]

    Sharpe EE, Rose CH, Tweet MS. “Obstetric anesthesia considerations in pregnancy-associated myocardial infarction: a focused review.” International journal of obstetric anesthesia (2024). PMID: 39227292 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Triggering Factors
  52. [52]

    McAlister C, Kang M, Alfadhel M et al.. “Thrombolysis in Spontaneous Coronary Artery Dissection-Angiographic Findings and Clinical Outcomes.” The Canadian journal of cardiology (2026). PMID: 41173456 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  53. [53]

    Geers J, Manral N, Park C et al.. “AI-quantified epicardial adipose tissue and prediction of future myocardial infarction in patients with cardiometabolic disease: a post-hoc analysis from the SCOT-HEART trial.” Cardiovascular diabetology (2025). PMID: 41126192 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  54. [54]

    Li J, Chen R, Zhou J et al.. “Effect of clonal hematopoiesis on plaque morphology and prognosis in patients with acute myocardial infarction.” Genome medicine (2025). PMID: 40855342 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  55. [55]

    Raphael CE, Sandoval Y, Beachey JD et al.. “Causes of Myocardial Infarction in Younger Patients: Troponin-Elevation in Persons ≤65 Years Old in Olmsted County.” Journal of the American College of Cardiology (2025). PMID: 40864006 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  56. [56]

    Stepanian A, Travers RJ, Tesfu A et al.. “Ponatinib, But Not the New Abl-Kinase Inhibitor Asciminib, Activates Platelets, Leukocytes, and Endothelial Cell TNF Signaling to Induce Atherosclerotic Plaque Inflammation, Myocardial Infarction, and Stroke.” Circulation (2025). PMID: 40762051 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  57. [57]

    Sun Q, Wang S, Zeng M et al.. “Impact of Carrying DNMT3A or TET2 Mutations on Plaque Characteristics and Prognosis in Patients With STEMI Based on OCT.” Circulation. Cardiovascular imaging (2025). PMID: 40755316 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  58. [58]

    Biccirè FG, Fabbiocchi F, Gatto L et al.. “Long-Term Prognostic Impact of OCT-Derived High-Risk Plaque Features: Extended Follow-Up of the CLIMA Study.” JACC. Cardiovascular interventions (2025). PMID: 40500004 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  59. [59]

    Hirose T, Fujii K, Hashimoto K et al.. “Plaque rupture and calcified nodules: major contributors to out-of-hospital cardiac arrest in acute myocardial infarction.” Cardiovascular intervention and therapeutics (2025). PMID: 40478392 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  60. [60]

    Xu C, Yang ML, Kho PF et al.. “Cross-Ancestry Associations of Spontaneous Coronary Artery Dissection Genetic Risk With Coronary Atherosclerosis and Migraine Headache.” Journal of the American Heart Association (2025). PMID: 40357661 ↗

    L5OTHERCited in: Etiology and Triggering Factors
  61. [61]

    Giangiacomi F, Popelier B, Lochy S et al.. “OPENing a new ECLECTIC approach to NSTEMI and cardiac arrest using ECG-less coronary computed tomography angiography. Study design and rationale of two prospective clinical studies.” Cardiovascular revascularization medicine : including molecular interventions (2026). PMID: 41314866 ↗

    L2bTRIAL_NONRANDOMCited in: Differential Diagnosis
  62. [62]

    Raat W, Nees L, Vaes B. “Diagnostic accuracy of signs and symptoms in acute coronary syndrome and acute myocardial infarction.” Scandinavian journal of primary health care (2025). PMID: 39308022 ↗

    L2aSR_OBSCited in: Differential Diagnosis
  63. [63]

    Kharawala A, Nagraj S, Setia G et al.. “Cardiac Critical Care of the Cardio-Obstetric Patient.” Journal of intensive care medicine (2026). PMID: 39819322 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  64. [64]

    Ricci F, Martini C, Scordo DM et al.. “ECG Patterns of Occlusion Myocardial Infarction: A Narrative Review.” Annals of emergency medicine (2025). PMID: 39818676 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  65. [65]

    Gamboa S, Shenvi C. “The great imitator: Hyperkalemia presenting with paralysis and ST segment elevations.” The American journal of emergency medicine (2026). PMID: 41274182 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  66. [66]

    Di Leo M, Vasumini N, Maida A et al.. “Cardiac magnetic resonance imaging in myocardial infarction with non-obstructive coronary arteries (MINOCA): current and evolving perspectives.” Expert review of cardiovascular therapy (2025). PMID: 41103008 ↗

    L5REVIEW_NARRATIVECited in: Differential Diagnosis
  67. [67]

    Ceriani E, Berra S, Agozzino F et al.. “ST-segment elevation in acute pericarditis and myocardial involvement: electrocardiographic and clinical profiling.” Open heart (2026). PMID: 41850763 ↗

    L5OTHERCited in: Differential Diagnosis
  68. [68]

    Airaksinen KEJ, Teppo K, Vasankari T et al.. “Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction.” Journal of the American Heart Association (2026). PMID: 41757465 ↗

    L5OTHERCited in: Differential Diagnosis
  69. [69]

    Zhou Y, Chen C, Li J et al.. “Identification and Validation of Differentially Expressed mRNAs From Peripheral Leukocytes for Acute Stanford Type A Aortic Dissection.” Journal of the American Heart Association (2025). PMID: 41378480 ↗

    L5OTHERCited in: Differential Diagnosis
  70. [70]

    Li L, Liu Y, Wu Y et al.. “Comparison of the cardiac troponin I-cardiac troponin T-troponin C complex and cardiac troponin I and T in distinguishing myocardial infarction using a single sample at presentation.” Clinical chemistry and laboratory medicine (2026). PMID: 41213158 ↗

    L5OTHERCited in: Differential Diagnosis
  71. [71]

    Andreß S, Melnic R, Christow H et al.. “Right-sided cardiogenic shock from acute pulmonary tumor thrombotic microangiopathy: a rare but deadly cardio-oncologic and metabolic emergency.” Clinical research in cardiology : official journal of the German Cardiac Society (2026). PMID: 40954305 ↗

    L5OTHERCited in: Differential Diagnosis
  72. [72]

    Zhou P, Zhang J, Wu X et al.. “Differential diagnosis of acute myocardial infarction based on plasma Exosomal MicroRNA.” International journal of legal medicine (2026). PMID: 40850945 ↗

    L5OTHERCited in: Differential Diagnosis
  73. [73]

    Snavely A, Jackson L, Hunter CJ et al.. “Differentiating Type 1 and Type 2 myocardial infarction using a machine learning algorithm and biomarkers.” The American journal of emergency medicine (2025). PMID: 40834835 ↗

    L5OTHERCited in: Differential Diagnosis
  74. [74]

    Du Z, Hu H, Shen C et al.. “Right Ventricular Strain as a Key Feature in Interpretable Machine Learning for Identification of Takotsubo Syndrome: A Multicenter CMR-based Study.” Academic radiology (2025). PMID: 40404506 ↗

    L5OTHERCited in: Differential Diagnosis
  75. [75]

    Sax DR, Warton EM, Mark DG et al.. “Emergency Department Triage Accuracy and Delays in Care for High-Risk Conditions.” JAMA network open (2025). PMID: 40314952 ↗

    L5OTHERCited in: Differential Diagnosis
  76. [76]

    Yildiz M, Pico M, Henry TD et al.. “Sex Differences in Patients Presenting With ST-Segment Elevation Myocardial Infarction and Nonobstructive Coronary Arteries.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 39906977 ↗

    L5OTHERCited in: Differential Diagnosis
  77. [77]

    Wang L, Wu H, Wu C et al.. “A deep-learning system integrating electrocardiograms and laboratory indicators for diagnosing acute aortic dissection and acute myocardial infarction.” International journal of cardiology (2025). PMID: 39880045 ↗

    L5OTHERCited in: Differential Diagnosis
  78. [78]

    Li L, Liu Y, Katrukha IA et al.. “Characterization of Cardiac Troponin Fragment Composition Reveals Potential for Differentiating Etiologies of Myocardial Injury.” Clinical chemistry (2025). PMID: 39697116 ↗

    L5OTHERCited in: Differential Diagnosis
  79. [79]

    Araoz PA, Gadam S, Bhanushali AK et al.. “Triple Rule Out CT in the Emergency Department: Clinical Risk and Outcomes (Triple Rule Out in the Emergency Department).” Academic radiology (2025). PMID: 39658473 ↗

    L5OTHERCited in: Differential Diagnosis
  80. [80]

    Airaksinen JKE, Tuominen T, Paana T et al.. “Novel troponin fragmentation assay to discriminate between Takotsubo syndrome and acute myocardial infarction.” European heart journal. Acute cardiovascular care (2024). PMID: 39422200 ↗

    L5OTHERCited in: Differential Diagnosis
  81. [81]

    Son JH, Park JK, Bang JH et al.. “Exosomal miRNAs Differentiate Chronic Total Occlusion from Acute Myocardial Infarction.” International journal of molecular sciences (2024). PMID: 39337705 ↗

    L5OTHERCited in: Differential Diagnosis
  82. [82]

    Seitz A, Dicpinigaitis AJ, Zhang C et al.. “Ischemic events are infrequent in patients with ovarian hyperstimulation syndrome.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2025). PMID: 39321946 ↗

    L5OTHERCited in: Differential Diagnosis
  83. [83]

    Yakovlev S, Gvozdeva A. “Left Ventricular Pericardial Strangulation: A Diagnostic Challenge in Acute Coronary Syndrome.” Methodist DeBakey cardiovascular journal (2026). PMID: 41725857 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  84. [84]

    Bui-Thi HD, Vu VH, Nguyen KD et al.. “Successful management of protracted anaphylaxis-induced severe acute respiratory distress syndrome masquerading as non-ST elevation myocardial infarction: a rare case report.” BMC cardiovascular disorders (2026). PMID: 41606487 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  85. [85]

    Dewi IP, Damayanti KR, Anggitama AM et al.. “Tackling the ST elevation in leptospirosis: A double-edged sword between bleeding and thrombosis - A case report.” Narra J (2025). PMID: 40951499 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  86. [86]

    Lacaita PG, Feuchtner GM. “Ruptured coronary aneurysm with fatal bleeding: a tricky differential diagnosis.” The international journal of cardiovascular imaging (2025). PMID: 40261595 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  87. [87]

    Ying HL, Zhao H, Zhang C et al.. “Pitfalls of computed tomography angiography examination in veno-arterial extracorporeal membrane oxygenation patients: a case report of a patient with cardiac rupture.” Journal of cardiothoracic surgery (2024). PMID: 39736763 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  88. [88]

    Raizner AE. “Myocardial Infarction with Normal Coronary Arteries.” Methodist DeBakey cardiovascular journal (2024). PMID: 39525371 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  89. [89]

    Gao S, An R, Wang C. “Tracheopericardial fistula in lung cancer masquerading as acute myocardial infarction: a case report.” BMC pulmonary medicine (2024). PMID: 39449137 ↗

    L4CASE_REPORTCited in: Differential Diagnosis
  90. [90]

    Haberman D, Verma B, Abusnina W et al.. “Low- Versus High-capacity Impella for CS After AMI: A Systematic Review and Pooled Data Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41507087 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  91. [91]

    Parlow S, Jung RG, Almoosawy SA et al.. “Prognostic Factors Among Patients Receiving Microaxial Flow Pump for Acute Myocardial Infarction-Related Cardiogenic Shock: A Systematic Review and Meta-Analysis.” Critical care medicine (2026). PMID: 41504526 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  92. [92]

    Scquizzato T, Grunau B, Fernando SM et al.. “Temporary mechanical circulatory support after return of spontaneous circulation following cardiac arrest: a systematic review and meta-analysis.” Resuscitation (2025). PMID: 41232590 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  93. [93]

    Obradovic D, Schulz L, Loncar G et al.. “Prognostic performance of cardiogenic shock 4 proteins prediction model in infarct-related cardiogenic shock.” ESC heart failure (2026). PMID: 41711227 ↗

    L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes
  94. [94]

    Sørensen R, Møller JE, Vandenbriele C et al.. “Bleeding in Patients With Infarct-Related Cardiogenic Shock: A DanGer Shock Substudy.” JACC. Cardiovascular interventions (2026). PMID: 41672689 ↗

    L1bRCTCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes
  95. [95]

    Jensen LO, Beske RP, Eiskjær H et al.. “Delay From First Symptoms in Patients Presenting With STEMI and Cardiogenic Shock: Insights From the DanGer Shock Trial.” Circulation. Cardiovascular interventions (2026). PMID: 41521915 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  96. [96]

    Kim MC, Ahn JH, Hyun DY et al.. “Complete revascularization timing in ST-segment elevation myocardial infarction and multivessel disease with heart failure: the OPTION-STEMI trial.” European heart journal (2026). PMID: 41493330 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  97. [97]

    Mangner N, Beske RP, Hassager C et al.. “Sex-Specific Microaxial Flow Pump Use and Outcomes in Infarct-Related Cardiogenic Shock in the DanGer Shock Trial.” Journal of the American College of Cardiology (2026). PMID: 41222528 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  98. [98]

    Nijveldt R, Maeng M, Beijnink CWH et al.. “Immediate or Deferred Nonculprit-Lesion PCI in Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41159879 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  99. [99]

    Laborante R, Paglianiti DA, Elia S et al.. “Safety and efficacy of early initiation of mineralocorticoid receptor antagonist after an acute decompensated heart failure event or acute myocardial infarction with cardiac dysfunction: a meta-analysis of randomized clinical trials.” ESC heart failure (2026). PMID: 41712413 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  100. [100]

    Sheng Z, Chen B. “Differences in the characteristics and outcomes of STEMI versus NSTEMI cardiogenic shock: A systematic review and meta-analysis.” Medicine (2025). PMID: 41189239 ↗

    L2aSR_OBSCited in: Supportive Care and Complication Management
  101. [101]

    Deng L, Gao Y, Pan L et al.. “Free Triiodothyronine as a Biomarker for Ventricular Arrhythmia Following Myocardial Infarction: A Multicenter Prospective Cohort Study.” Clinical interventions in aging (2026). PMID: 41867325 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management, Special Populations
  102. [102]

    Israeli Hadar Y, Haim M, Tsaban G et al.. “Impact of late ventricular fibrillation on postdischarge 1-year mortality of patients presenting with acute myocardial infarction: a nationwide retrospective study.” BMJ open (2025). PMID: 41469077 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  103. [103]

    Kloosterman M, Smits KC, Stoks J et al.. “Computer-aided characterization of the arrhythmogenic substrate after myocardial infarction.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2026). PMID: 41512109 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  104. [104]

    Thiele H, Hassager C. “Cardiogenic Shock.” The New England journal of medicine (2026). PMID: 41467651 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  105. [105]

    Marcos-Garcés V, Bertolín-Boronat C, Merenciano-González H et al.. “Left Ventricular Remodeling After Myocardial Infarction-Pathophysiology, Diagnostic Approach and Management During Cardiac Rehabilitation.” International journal of molecular sciences (2025). PMID: 41303447 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  106. [106]

    Spaeth LD, Rahim M, Kochar A et al.. “Cardiogenic Shock and Temporary Mechanical Circulatory Support.” The Medical clinics of North America (2025). PMID: 41136064 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  107. [107]

    Boettger P, Preusse-Sondermann H, Sedighi J et al.. “Acute kidney injury as a prognostic determinant in cardiogenic shock: a cohort study.” Clinical and experimental nephrology (2026). PMID: 41225284 ↗

    L2bCOHORTCited in: Supportive Care and Complication Management
  108. [108]

    Hassan AM, Aziz F, Tripolt NJ et al.. “Carbohydrate antigen 125 (CA125) following acute myocardial infarction: effects of empagliflozin and association with heart failure readouts in the EMMY trial.” Scientific reports (2025). PMID: 41430429 ↗

    L1bRCTCited in: Supportive Care and Complication Management
  109. [109]

    Filipescu R, Collins SP, Radu RI et al.. “Therapeutic Advances in the Management of Cardiogenic Shock.” American journal of therapeutics (Unknown). PMID: 41543923 ↗

    L5REVIEW_NARRATIVECited in: Supportive Care and Complication Management
  110. [110]

    Adi A, Jain R, Guru S et al.. “Antimicrobial Use in Acute Myocardial Infarction-Related Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41904804 ↗

    L5OTHERCited in: Supportive Care and Complication Management, Prognosis and Long-term Outcomes, Special Populations
  111. [111]

    Feng R, Hu L, Zhu Y et al.. “Association between TyG-related indices and in-hospital acute heart failure in patients with acute myocardial infarction after emergency percutaneous coronary intervention.” Frontiers in endocrinology (2026). PMID: 41869030 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  112. [112]

    Smyth D, Zhang L, Al-Khalaf M et al.. “Hematopoietic expression of cIAP2 drives inflammation and heart failure after myocardial infarction.” Nature cardiovascular research (2026). PMID: 41820671 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  113. [113]

    Wei Q, Zhou H, Sun J et al.. “SLC31A1 knockdown mitigates post-MI heart failure via regulation of copper metabolism.” Frontiers in immunology (2026). PMID: 41808820 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  114. [114]

    Wybraniec MT, Sufryd A, Cichoń M et al.. “Cardiogenic shock in the course of myocardial infarction: the results of the Shock-POL registry.” ESC heart failure (2026). PMID: 41746839 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  115. [115]

    Han T, Wen X, Guo Y et al.. “E3 ubiquitin ligase TRIM21-mediated K48-linked ubiquitination of ALDH2 rs671 mutant promotes adverse cardiac remodeling.” JCI insight (2026). PMID: 41734032 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  116. [116]

    Cheng M, Li L, Huang X et al.. “Linggui Zhugan Decoction mitigates post-myocardial infarction heart failure through modulation of cardiomyocyte F-actin cytoskeletal organization.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 41655544 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  117. [117]

    Zhou MM, Xu L, Huang DZ et al.. “KCNQ2 downregulation in left stellate ganglion neurons exacerbates malignant ventricular arrhythmias after myocardial infarction.” Journal of molecular and cellular cardiology (2026). PMID: 41654290 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  118. [118]

    Semedzhieva NE, Tsakova A, Lozanova V et al.. “17β-Estradiol Does Not Designate Non-Sex-Specific Early Ventricular Arrhythmia in Acute Myocardial Infarction, in Contrast to C-Reactive Protein.” International journal of molecular sciences (2026). PMID: 41596617 ↗

    L5OTHERCited in: Supportive Care and Complication Management
  119. [119]

    Chiotis S, Giannopoulos G, Boulmpou A et al.. “Association of common risk factors with major adverse cardiac events and mortality in patients with MINOCA: A systematic review and meta-analysis.” International journal of cardiology (2026). PMID: 41655606 ↗

    L2aSR_OBSCited in: Prognosis and Long-term Outcomes
  120. [120]

    Shen X, Zhang H, Li Z et al.. “Post-PCI Global QFR and Long-Term Outcomes in ACS: Findings From the FAVOR III China Trial.” JACC. Cardiovascular interventions (2026). PMID: 41986039 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations
  121. [121]

    Passo BD, Tonet E, Lanzilotti V et al.. “Consistent benefit of physiology-guided complete revascularization across the spectrum of frailty in older patients with myocardial infarction: a prespecified analysis of the FIRE trial.” Age and ageing (2026). PMID: 41965249 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations
  122. [122]

    Choi KH, Kang D, Kim W et al.. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41910427 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations
  123. [123]

    Sans-Roselló J, Fernández-Peregrina E, Kuku KO et al.. “Timing of cardiogenic shock and clinical outcomes in takotsubo syndrome: A multicenter cohort study.” International journal of cardiology (2026). PMID: 41765143 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  124. [124]

    Madhavan MV, Gregson J, Redfors B et al.. “Spontaneous Myocardial Infarction After Left Main Revascularization: The EXCEL Trial.” Circulation (2026). PMID: 41664927 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes
  125. [125]

    Liu Y, Liu X, Sun D et al.. “Aspirin Combined With Ticagrelor or Clopidogrel in STEMI Patients With Diabetes Mellitus and Poor Glycemic Control Undergoing Primary PCI: A Multicenter Retrospective Cohort Study.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41656976 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  126. [126]

    Heuts S, Pustjens TF, Lux Á et al.. “Probabilities of treatment effects in complete or culprit-only revascularization for NSTEMI: A Bayesian re-analysis of the SLIM trial.” American heart journal (2026). PMID: 41654213 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes
  127. [127]

    Zhao P, Li ZX, Jiang EL et al.. “Acute myocardial infarction following allogeneic hematopoietic stem cell transplantation: A national cohort study.” Cancer letters (2026). PMID: 41628833 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  128. [128]

    Huang DS, Fang CY, Hsueh SK et al.. “Predictors of Clinical Outcomes in Myocardial Infarction Patients Underwent Coronary Intervention With Rotational Atherectomy: A Single-Center Retrospective Study in Southern Taiwan.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2026). PMID: 41623217 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  129. [129]

    Armstrong PW, Zheng Y, Welsh RC et al.. “Primary percutaneous coronary intervention within the first hour: Insights from early-treated patients with ST-elevation myocardial infarction.” American heart journal (2026). PMID: 41619999 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes
  130. [130]

    Wang B, Song Y, Fan Y et al.. “Association of Initial Laxative Strategy With Clinical Outcomes in Critically Ill Patients With Acute Myocardial Infarction: A Retrospective Cohort Study.” Cardiovascular therapeutics (2026). PMID: 41964389 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations
  131. [131]

    Zhou T, Yang K, Yang Y et al.. “Complete Blood Count-Derived Inflammation Indices to Predict 3-Year All-Cause Mortality in Patients With Diabetes and Acute Myocardial Infarction in Critical Care: Retrospective Cohort Study With Single-Center External Validation.” JMIR medical informatics (2026). PMID: 41818746 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations
  132. [132]

    Spadafora L, Bernardi M, Biondi-Zoccai G et al.. “GRACE score for risk stratification and completeness of revascularization in older patients with myocardial infarction.” Journal of cardiovascular medicine (Hagerstown, Md.) (2026). PMID: 41860766 ↗

    L1bRCTCited in: Prognosis and Long-term Outcomes, Special Populations
  133. [133]

    Zhao X, Chen R, Li J et al.. “Utility of Novel Lipid Parameters for Risk Stratification in Patients with Diabetes and STEMI-from a Prospective Study.” Vascular health and risk management (2026). PMID: 41877706 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes, Special Populations
  134. [134]

    Nyanga AF, Mohamed J, Msunza M et al.. “Performance of the Grace ACS Risk Score in Predicting in-Hospital and Six-Month Mortality in Patients with ACS: A Single Center Retrospective Cohort Study.” Vascular health and risk management (2026). PMID: 41736925 ↗

    L2bCOHORTCited in: Prognosis and Long-term Outcomes
  135. [135]

    Sundh J, Parker WAE, Oldgren J et al.. “Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts.” International journal of chronic obstructive pulmonary disease (2026). PMID: 41947782 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes, Special Populations
  136. [136]

    Yarahmadi P, Hedlin H, Bates S et al.. “Survival After the First Myocardial Infarction in Older Women: A Prospective Cohort Analysis From the WHI.” Journal of the American Heart Association (2026). PMID: 41848053 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  137. [137]

    Dahiya G, Bohman JK, Tonna JE et al.. “Acid-Base Status During Venoarterial Extracorporeal Membrane Oxygenator Support in Patients With Cardiogenic Shock.” Journal of the American Heart Association (2026). PMID: 41823232 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  138. [138]

    Elbadawi A, Chen A, Wojdyla D et al.. “Contemporary Trends, Characteristics, and Outcomes of Patients Undergoing Percutaneous Coronary Intervention for Stent Thrombosis.” JACC. Cardiovascular interventions (2026). PMID: 41813273 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  139. [139]

    Kwon Y, Kim N, Kim DH et al.. “Long-Term Clinical Outcomes of Acute Myocardial Infarction Based on Institutional Experience With IVUS.” Journal of the American Heart Association (2026). PMID: 41757462 ↗

    L5OTHERCited in: Prognosis and Long-term Outcomes
  140. [140]

    Sharma M, Dong Q, Hirano T et al.. “Asundexian for Secondary Stroke Prevention.” The New England journal of medicine (2026). PMID: 41985132 ↗

    L1bRCTCited in: Special Populations
  141. [141]

    Delewi R, Aarts HM, Broeze GM et al.. “Deferral of percutaneous coronary intervention in patients undergoing transcatheter aortic valve implantation (PRO-TAVI): an investigator-initiated, multicentre, open-label, non-inferiority, randomised controlled trial.” Lancet (London, England) (2026). PMID: 41921523 ↗

    L1bRCTCited in: Special Populations
  142. [142]

    Kang J, Park S, Yang HM et al.. “Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention: 10-year follow-up of the HOST-EXAM trial.” Lancet (London, England) (2026). PMID: 41921522 ↗

    L1bRCTCited in: Special Populations
  143. [143]

    Marcadenti A, Bersch-Ferreira AC, Vieira Machado RH et al.. “Supplementation with mixed nuts does not improve inflammatory biomarkers or dietary inflammatory potential in post-myocardial infarction: a secondary analysis of the DICA-NUTS trial.” Nutrition, metabolism, and cardiovascular diseases : NMCD (2026). PMID: 41856832 ↗

    L1bRCTCited in: Special Populations
  144. [144]

    Sundqvist MO, Wärme J, Hjort M et al.. “Helicobacter pylori, Inflammation, and Long-Term Outcome in Patients With Acute Myocardial Infarction: A Prospective Cohort Study.” Helicobacter (2026). PMID: 41834132 ↗

    L2bCOHORTCited in: Special Populations
  145. [145]

    Asadi N, Azarbarzin M, Salmani F. “The effect of early mobilization program on changes in hemodynamic symptoms in patients with acute myocardial infarction.” Journal of bodywork and movement therapies (2026). PMID: 41927220 ↗

    L1bRCTCited in: Special Populations
  146. [146]

    Wang H, Chou E, Robinson RD et al.. “Federated Meta-Analysis of HEART Score Performance for Emergency Department Chest Pain.” Academic emergency medicine : official journal of the Society for Academic Emergency Medicine (2026). PMID: 41943236 ↗

    L2aSR_OBSCited in: Special Populations
  147. [147]

    Turchin A, Shubina M, Morrison FJ et al.. “Cumulative excess weight exposure over time and cardiovascular risk: A prospective cohort study.” PloS one (2026). PMID: 41950162 ↗

    L2bCOHORTCited in: Special Populations
  148. [148]

    Nesova A, Vorobeva D, Ryabov V. “Impact of the risk-treatment paradox on in-hospital and long-term outcomes in patients with very high-risk non-ST-elevation acute coronary syndrome.” The Indian journal of medical research (2026). PMID: 41934433 ↗

    L5REVIEW_NARRATIVECited in: Special Populations
  149. [149]

    Shen YC, Sarkar N, Hsia RY. “Community-Level Procedure Volume and Patient Health Profiles Following PCI-Capable Facility Openings.” JAMA network open (2026). PMID: 41910975 ↗

    L5OTHERCited in: Special Populations
  150. [150]

    Cars T, Gustafsson S, Chan Q et al.. “Methodological Challenges of Emulating a Target Trial to Assess Effectiveness of Timing of PCSK9 Inhibitor Treatment Initiation Post Myocardial Infarction.” Pharmacoepidemiology and drug safety (2026). PMID: 41902372 ↗

    L5OTHERCited in: Special Populations
  151. [151]

    Chen Y, Chang A, Cheng F et al.. “A nomogram for predicting in-hospital death in a multinational cohort of patients with takotsubo syndrome.” European journal of clinical investigation (2026). PMID: 41888991 ↗

    L5OTHERCited in: Special Populations
  152. [152]

    Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026.” Cardiovascular intervention and therapeutics (2026). PMID: 41749019 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  153. [153]

    Rao SV, O'Donoghue ML, Ruel M et al.. “2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Circulation (2025). PMID: 40014670 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  154. [154]

    Ozaki Y, Tobe A, Onuma Y et al.. “CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2024.” Cardiovascular intervention and therapeutics (2024). PMID: 39302533 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  155. [155]

    Mahmud E, Dauerman HL, Welt FGP et al.. “Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP).” Journal of the American College of Cardiology (2020). PMID: 32330544 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  156. [156]

    Baran DA, Grines CL, Bailey S et al.. “SCAI clinical expert consensus statement on the classification of cardiogenic shock: This document was endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Society of Critical Care Medicine (SCCM), and the Society of Thoracic Surgeons (STS) in April 2019.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2019). PMID: 31104355 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  157. [157]

    Charpentier S, Chenevier-Gobeaux C. “[2015 ESC guidelines: 1-hour rule-out and rule-in of acute myocardial infarction with high-sensitive troponin T].” Presse medicale (Paris, France : 1983) (2016). PMID: 27374265 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  158. [158]

    Beygui F, Castren M, Brunetti ND et al.. “Pre-hospital management of patients with chest pain and/or dyspnoea of cardiac origin. A position paper of the Acute Cardiovascular Care Association (ACCA) of the ESC.” European heart journal. Acute cardiovascular care (2020). PMID: 26315695 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  159. [159]

    Qaseem A, Fihn SD, Williams S et al.. “Diagnosis of stable ischemic heart disease: summary of a clinical practice guideline from the American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons.” Annals of internal medicine (2012). PMID: 23165664 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  160. [160]

    George JC, Dangas GD. “2009 Focused updates to guidelines in ST-elevation myocardial infarction and percutaneous coronary intervention: application to interventional cardiology.” JACC. Cardiovascular interventions (2010). PMID: 20170887 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  161. [161]

    Pollack CV, Antman EM, Hollander JE. “2007 focused update to the ACC/AHA guidelines for the management of patients with ST-segment elevation myocardial infarction: implications for emergency department practice.” Annals of emergency medicine (2008). PMID: 18519158 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  162. [162]

    Hesse B, Lindhardt TB, Acampa W et al.. “EANM/ESC guidelines for radionuclide imaging of cardiac function.” European journal of nuclear medicine and molecular imaging (2008). PMID: 18224320 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  163. [163]

    Campbell-Scherer DL, Green LA. “ACC/AHA guideline update for the management of ST-segment elevation myocardial infarction.” American family physician (2009). PMID: 19530638 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  164. [164]

    Thiele H, Desch S, de Waha S. “[Acute myocardial infarction in patients with ST-segment elevation myocardial infarction : ESC guidelines 2017].” Herz (2017). PMID: 29119223 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  165. [165]

    Schäfer A, Bauersachs J. “[Focused update on dual antiplatelet treatment : ESC guidelines 2017].” Herz (2017). PMID: 29043405 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  166. [166]

    Pollack CV, Hollander JE, Chen AY et al.. “Non-ST-elevation myocardial infarction patients who present during off hours have higher risk profiles and are treated less aggressively, but their outcomes are not worse: a report from Can Rapid Risk Stratification of Unstable Angina Patients Suppress ADverse Outcomes with Early Implementation of the ACC/AHA Guidelines CRUSADE initiative.” Critical pathways in cardiology (2009). PMID: 19258835 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  167. [167]

    . “[Guidelines of the American College of Cardiology/American Heart Association 2007 for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction. Part VI].” Kardiologiia (2008). PMID: 18991825 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  168. [168]

    Massberg S, Polzin A. “[Update ESC-Guideline 2017: Dual Antiplatelet Therapy].” Deutsche medizinische Wochenschrift (1946) (2018). PMID: 30060279 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  169. [169]

    Hochholzer W, Neumann FJ. “[The new 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation].” Deutsche medizinische Wochenschrift (1946) (2016). PMID: 27254627 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  170. [170]

    Pepi M, Evangelista A, Nihoyannopoulos P et al.. “Recommendations for echocardiography use in the diagnosis and management of cardiac sources of embolism: European Association of Echocardiography (EAE) (a registered branch of the ESC).” European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology (2010). PMID: 20702884 ↗

    L1cGUIDELINECited in: Guidelines and Resources
  171. [171]

    . “API expert consensus document on management of ischemic heart disease.” The Journal of the Association of Physicians of India (2006). PMID: 16909697 ↗

    L1cGUIDELINECited in: Guidelines and Resources

Revision History

All updates applied to this page

Loading revisions…